DRPLA Natural History and Biomarkers Study
This study aims to recruit paediatric and adult DRPLA mutation carriers and healthy controls across different countries. It aims to characterize the natural history of DRPLA in both juvenile- and adult-onset patients. It also aims to identify clinical, genetic, fluid and imaging biomarkers that can be used for different purposes, such as disease progression biomarkers. With time, it will provide a platform to support the design and conduct of clinical trials. Participants that cannot travel to study sites or live in countries with no study sites could be able to participate in the study. Please contact the study staff is that is your case.
ClinicalTrials.gov Link: clinicaltrials.med.nyu.edu/clinicaltrial/1929/dentatorubral-pallidoluysian-atrophy-natural-history/
About the Study
Eligible Ataxia Types
Dentatorubral-pallidoluysian atrophy (DRPLA)
Type of Study
Research Study
Clinical Trial Phase
N/A
Age Range
Children and Adult 18+
Study Start Date
06/01/2022
Estimated Completion Date
12/31/2024
IRB Approval #
S21-00506
Location(s)
NYU Grossman School of Medicine
222 East 41st Street, 13th Floor
New York, NY
Additional Sites:
Chapel Hill, NC
London, UK
Download contact info for additional sites
Contact Information
Danika Anganoo-Khan
Danika.Anganoo-Khan@nyulangone.org
929-455-5629
Binu Joseph
Binu.Joseph@nyulangone.org
929-455-5625
What does participation in the study entail?
Participants will have an annual visit for three years (baseline visit and two follow-up visits). The DRPLA NHBS aims to collect natural history information for the different clinical features which are characteristic of DRPLA (e.g. ataxia, choreoathetosis, dementia, cognitive impairment, seizures, myoclonus). The protocol includes scales and questionnaires that are crucial to capture the progression of this condition in its multi-systemic aspects and that will contribute to instruct future trial design. Participants will also be offered the opportunity to collect biomaterials and brain MRI to investigate valid biomarkers.
What are the potential benefits for participants?
We aim to increase our understanding of DRPLA, and so will improve the information that we are able to give out to patients in clinic regarding prognosis and quality of life, and will allow better planning of therapeutic trials, which may lead to better treatments.
What are the potential risks for participants?
None listed.
Is there financial compensation?
No.
Is there travel reimbursement?
Yes.
Who is eligible?
DRPLA mutation carriers and healthy controls.
View Other Research Opportunities
Deep Brain Stimulation of the Deep Cerebellar Nuclei in Subjects with Spinocerebellar Ataxia: A Safety and Feasibility Study
The goal/purpose of the study is to evaluate the safety and feasibility of deep brain stimulation (DBS) in the deep cerebellar nuclei (DCN) in patients with Spinocerebellar Ataxia (SCA) types Read More…
Clinical Outcome Assessment and Treatment Monitoring Markers for Clinical Trial Readiness in FXTAS
The purpose of this research is to prepare for future FXTAS (fragile X-associated tremor/ataxia syndrome) clinical trials by establishing a set of accurate and clinically important measures to sensitively track Read More…
The role of the cerebellum in speech production
This research aims to characterize the role of the cerebellum in speech motor control. This work will help us understand how the cerebellum works and may lead to the development Read More…
